Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a “me too” drug?

References

• SiegelRLMillerKDJemalACancer Statistics, 2017CA Cancer J Clin2017671 73028055103
   PubMed Web of Science ®Google Scholar
• GoelGChauhanAHoseinPJRamucirumab: a novel antiangiogenic agent in the treatment of metastatic colorectal cancerCurr Colorectal Cancer Rep2016125 232240
   Google Scholar
• MyintZWGoelGRole of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progressJ Hematol Oncol2017101 8628434400
   PubMedGoogle Scholar
• FerraraNVascular endothelial growth factor as a target for anticancer therapyOncologist20049Suppl 1 21015178810
   PubMed Web of Science ®Google Scholar
• EllisLMHicklinDJVEGF-targeted therapy: mechanisms of anti-tumour activityNat Rev Cancer200888 57959118596824
   PubMed Web of Science ®Google Scholar
• AugustinHGKohGYThurstonGAlitaloKControl of vascular morphogenesis and homeostasis through the angiopoietin-Tie systemNat Rev Mol Cell Biol2009103 16517719234476
   PubMed Web of Science ®Google Scholar
• YancopoulosGDDavisSGaleNWRudgeJSWiegandSJHolashJVascular-specific growth factors and blood vessel formationNature20004076801 24224811001067
   PubMed Web of Science ®Google Scholar
• WilhelmSMDumasJAdnaneLRegorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInt J Cancer20111291 24525521170960
   PubMed Web of Science ®Google Scholar
• WilhelmSMCarterCTangLBAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisCancer Res20046419 7099710915466206
   PubMed Web of Science ®Google Scholar
• WilhelmSAdnaneLHirth-DietrichCEhrlichPLynchMPreclinical characterization of BAY 73-4506: a kinase inhibitor with broad spectrum antitumor activity targeting oncogenic and angiogenic kinasesAACR Meeting Abstracts2007611 B260
   Google Scholar
• SacreALanthierNDanoHRegorafenib induced severe toxic hepatitis: characterization and discussionLiver Int20163611 1590159427500989
   PubMed Web of Science ®Google Scholar
• ZopfDScholzAFichtnerIBeckerMMüllerTKisselMRegorafenib (BAY 73-4506): a broad spectrum tumor deactivator with high combinability potential and antimetastasis activityAACR; Cancer Res2011718 Suppl Abstract 4262
   Google Scholar
• ZopfDFichtnerIBhargavaAPharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical modelsCancer Med2016511 3176318527734608
   PubMed Web of Science ®Google Scholar
• SchmiederRHoffmannJBeckerMRegorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancerInt J Cancer20141356 1487149624347491
   PubMed Web of Science ®Google Scholar
• StrumbergDScheulenMESchultheisBRegorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I studyBr JCancer201210611 1722172722568966
   PubMed Web of Science ®Google Scholar
• SajithlalGBHamedHACruickshanksNSorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cellsMol Pharmacol2013844 56257123877009
   PubMed Web of Science ®Google Scholar
• MrossKFrostASteinbildSA phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumorsClin Cancer Res2012189 2658266722421192
   PubMed Web of Science ®Google Scholar
• HedbomSSteinbildSFrostAPhase I study of BAY 73-4506 a multikinase inhibitor, administered for 21 days on/7 days off in patients with advanced solid tumorsJ Clin Oncol20072518 Suppl 3593
   Google Scholar
• ShimizuTTolcherAWPatnaikAPhase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumorsJ Clin Oncol20102815 Suppl 303520458031
   PubMed Web of Science ®Google Scholar
• SunakawaYFuruseJOkusakaTRegorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokineticsInvest New Drugs2013321 10411223553067
   PubMed Web of Science ®Google Scholar
• SchultheisBFolprechtGKuhlmannJRegorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib studyAnn Oncol2013246 1560156723493136
   PubMed Web of Science ®Google Scholar
• ArgilésGTroianiTRiveraFFirst-line treatment with regorafenib (REG) in combination with mFOLFOX6 (folinic acid+5-fluorouracil [5-FU]+oxaliplatin) for metastatic colorectal cancer (mCRC): a single-arm, open-label phase II clinical trialThe 17th European Cancer Congress (ECCO)September 27, 2013Amsterdam
   Google Scholar
• GrotheyAVan CutsemESobreroARegorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialLancet20133819863 30331223177514
   PubMed Web of Science ®Google Scholar
• YoshinoTKomatsuYYamadaYRandomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulationsInvest New Drugs2015333 74075025213161
   PubMed Web of Science ®Google Scholar
• LiJQinSXuRRegorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncol2015166 61962925981818
   PubMed Web of Science ®Google Scholar
• TougeronDDesseigneFEtiennePLREBECCA: a large cohort study of regorafenib (REG) in the real-life setting in patients (pts) previously treated for metastatic colorectal cancer (mCRC)Ann Oncol201425Suppl 4 iv167iv209 Abstr 6220 ESMO2014
   Google Scholar
• Van CutsemECiardielloFSeitzJ-FLBA-05 Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancerAnnOncol201526Suppl 4 iv118
   Google Scholar
• GrotheyAVan CutsemESobreroAFTime course of regorafenib-associated adverse events in the phase III CORRECT studyJ Clin Oncol201230Suppl 34 467
   Google Scholar
• FalconeAVan CutsemESobreroARegorafenib dose modifications in patients with metastatic colorectal cancer in the phase III CORRECT studyThe 17th European Cancer Congress (ECCO)September 27, 2013Amsterdam
   Google Scholar
• SuedaTSakaiDKudoTEfficacy and safety of regorafenib or TAS-102 in patients with metastatic colorectal cancer refractory to standard therapiesAnticancer Res2016368 4299430627466548
   PubMed Web of Science ®Google Scholar
• MoriwakiTFukuokaSTaniguchiHPropensity score analysis of regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): a Japanese society for cancer of the colon and rectum multicenter observational studyOncologist Epub2017911
   Web of Science ®Google Scholar
• TabchiSGhosnMRegorafenib: start low and go slowTarget Oncol2015103 44544725548130
   PubMed Web of Science ®Google Scholar
• GrotheyARegorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendationsClin Adv Hematol Oncol2015138 51451726351814
   PubMedGoogle Scholar
• SienaSGrotheyASobreroAEffects of regorafenib therapy on health-related quality of life in patients with metastatic colorectal cancer in the phase III CORRECT studyThe 17th European Cancer Congress (ECCO)September 27, 2013Amsterdam
   Google Scholar
• ChangJPawarVGrotheyATime to health status deterioration in regorafenib-treated patients with metastatic colorectal cancer (mCRC): a post-hoc analysis of the phase III CORRECT studyThe 17th European Cancer Congress (ECCO)September 27, 2013Amsterdam
   Google Scholar
• SealBSCost-effectiveness of regorafenib for pretreated metastatic colorectal cancer patients in the United StatesJ Clin Oncol201230Suppl 34 578
   Google Scholar
• GoldsteinDAAhmadBBChenQCost-effectiveness analysis of regorafenib for metastatic colorectal cancerJ Clin Oncol20153332 3727373226304904
   PubMed Web of Science ®Google Scholar
• ChoiHCharnsangavejCFariaSCCorrelation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteriaJ Clin Oncol20072513 1753175917470865
   PubMed Web of Science ®Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 11)Eur J Cancer2009452 22824719097774
   PubMed Web of Science ®Google Scholar
• MaromEMMartinezCHTruongMTTumor cavitation during therapy with antiangiogenesis agents in patients with lung cancerJ Thorac Oncol200834 35135718379352
   PubMed Web of Science ®Google Scholar
• RicottaRSartore-BianchiAVerrioliAVanzulliASienaSRegorafenib for metastatic colorectal cancerLancet20133819877 1537
   PubMedGoogle Scholar
• RicottaRVerrioliAGhezziSRadiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post-hoc analysis of the CORRECT phase III trial (RadioCORRECT study)ESMO Open201616 e00011128848658
   PubMedGoogle Scholar
• LimYHanSWYoonJHClinical implication of anti-angiogenic effect of regorafenib in metastatic colorectal cancerPLoS One20151012 e014500426671465
   PubMed Web of Science ®Google Scholar
• AdenisAde la FouchardiereCPauleBSurvival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use programBMC cancer20161641227389564
   PubMed Web of Science ®Google Scholar
• CalcagnoFLenobleSLakkisZEfficacy, safety and cost of regorafenib in patients with metastatic colorectal cancer in French clinical practiceClin Med Insights Oncol201610596627398042
   PubMedGoogle Scholar
• Del PreteSCennamoGLeoLAdherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life studyFuture Oncol2017135 41542327780365
   PubMed Web of Science ®Google Scholar
• GotfritJVickersMSudSReal-life treatment of metastatic colorectal cancer with regorafenib: a single-centre reviewCurr Oncol2017244 23423928874891
   PubMed Web of Science ®Google Scholar
• KopeckovaKBuchlerTBortlicekZRegorafenib in the real-life clinical practice: data from the Czech registryTarget Oncol2017121 899527638381
   PubMed Web of Science ®Google Scholar
• PadhaniARLeachMOAntivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imagingAbdom Imaging2005303 32434115688112
   PubMedGoogle Scholar
• MrossKFasolUFrostADCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I studyJ Angiogenes Res20091519946413
   PubMedGoogle Scholar
• EschbachRSClevertDAHirner-EppenederHContrast-enhanced ultrasound with VEGFR2-targeted microbubbles for monitoring regorafenib therapy effects in experimental colorectal adenocarcinomas in rats with DCE-MRI and immunohistochemical validationPLoS One2017121 e016932328060884
   PubMed Web of Science ®Google Scholar
• KomoriATaniguchiHHamauchiSSerum CA19-9 response is an early predictive marker of efficacy of regorafenib in refractory metastatic colorectal cancerOncology Epub201792
   Google Scholar
• SuenagaMMashimaTKawataNSerum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancerOncotarget2016723 348113482327166185
   PubMedGoogle Scholar
• TaberneroJLenzHJSienaSAnalysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trialLancet Oncol2015168 93794826184520
   PubMed Web of Science ®Google Scholar
• DressmanDYanHTraversoGKinzlerKWVogelsteinBTransforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variationsProc Natl Acad Sci USA200310015 8817882212857956
   PubMed Web of Science ®Google Scholar
• DiehlFLiMDressmanDDetection and quantification of mutations in the plasma of patients with colorectal tumorsProc Natl Acad Sci USA200510245 163681637316258065
   PubMed Web of Science ®Google Scholar
• MaedaAAndoHUraTAssociation between ABCG2 and SLCO1B1 polymorphisms and adverse drug reactions to regorafenib: a preliminary studyInt J Clin Pharmacol Ther2017555 40941528157071
   PubMed Web of Science ®Google Scholar
• ChenDWeiLYuJZhangLRegorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosisClin Cancer Res20142013 3472348424763611
   PubMed Web of Science ®Google Scholar